NasdaqGM - Delayed Quote USD
Summit Therapeutics Inc. (SMMT)
24.29
+0.09
+(0.37%)
At close: 4:00:01 PM EDT
24.29
0.00
(0.00%)
After hours: 4:05:14 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0.00
0.00
0.00
705.00k
1.81M
Operating Expense
250.43M
225.97M
609.68M
64.33M
87.98M
Operating Income
-250.43M
-225.97M
-609.68M
-63.62M
-86.17M
Net Non Operating Interest Income Expense
7.90M
4.78M
-6.06M
-2.89M
-242.00k
Other Income Expense
1.80M
-97.00k
780.00k
-12.27M
-2.17M
Pretax Income
-240.73M
-221.29M
-614.96M
-78.78M
-88.60M
Tax Provision
--
--
--
--
0.00
Net Income Common Stockholders
-240.75M
-221.31M
-614.93M
-78.78M
-88.60M
Diluted NI Available to Com Stockholders
-240.75M
-221.31M
-614.93M
-78.78M
-88.60M
Basic EPS
-0.34
-0.31
-0.99
-0.41
-0.96
Diluted EPS
-0.34
-0.31
-0.99
-0.41
-0.96
Basic Average Shares
727.61M
718.54M
619.65M
193.34M
92.29M
Diluted Average Shares
727.61M
718.54M
619.65M
193.34M
92.29M
Total Operating Income as Reported
--
-226.00M
-609.65M
-72.09M
-86.19M
Total Expenses
250.43M
225.97M
609.68M
64.33M
87.98M
Net Income from Continuing & Discontinued Operation
-240.75M
-221.31M
-614.93M
-78.78M
-88.60M
Normalized Income
-242.56M
-221.22M
-615.96M
-66.20M
-86.47M
Interest Income
--
13.47M
10.40M
1.51M
0.00
Interest Expense
5.57M
8.69M
16.46M
4.40M
242.00k
Net Interest Income
7.90M
4.78M
-6.06M
-2.89M
-242.00k
EBIT
-235.16M
-212.60M
-598.50M
-74.38M
-88.36M
EBITDA
-235.08M
-212.51M
-598.30M
-73.12M
-85.91M
Reconciled Depreciation
87.00k
89.00k
198.00k
1.26M
2.46M
Net Income from Continuing Operation Net Minority Interest
-240.75M
-221.31M
-614.93M
-78.78M
-88.60M
Total Unusual Items Excluding Goodwill
1.80M
-97.00k
1.03M
-12.58M
-2.13M
Total Unusual Items
1.80M
-97.00k
1.03M
-12.58M
-2.13M
Normalized EBITDA
-236.88M
-212.42M
-599.34M
-60.54M
-83.77M
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
0.00
0.00
0.00
0.00
0.00
12/31/2021 - 3/5/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VKTX Viking Therapeutics, Inc.
27.56
+2.04%
TGTX TG Therapeutics, Inc.
34.85
-0.03%
SRPT Sarepta Therapeutics, Inc.
36.72
-21.45%
CYTK Cytokinetics, Incorporated
33.04
-2.74%
RGLS Regulus Therapeutics Inc.
7.85
+0.26%
IOVA Iovance Biotherapeutics, Inc.
3.1300
+0.97%
IBRX ImmunityBio, Inc.
1.8900
-5.97%
VRTX Vertex Pharmaceuticals Incorporated
434.82
-3.38%
BBIO BridgeBio Pharma, Inc.
35.82
-3.03%
RXRX Recursion Pharmaceuticals, Inc.
4.1900
+0.84%